Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Hamilton Lane INC Director's Dealing 2017

Mar 8, 2017

30753_dirs_2017-03-08_f20fe7a4-baec-4b30-ab74-f002b07c5721.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hamilton Lane INC (HLNE)
CIK: 0001433642
Period of Report: 2017-03-06

Reporting Person: Delgado-Moreira Juan (Managing Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-06 Class A Common Stock J 1550965 Acquired 1550965 Direct
2017-03-06 Class A Common Stock P 2800 $16 Acquired 1553765 Direct
2017-03-06 Restricted Class A Common Stock J 77868 Acquired 1628833 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-06 Employee Stock Option (right to buy) $1.34 J 233495 Acquired 2017-06-01 Class A Common Stock (233495.0) Direct

Footnotes

F1: In the reorganization (the "Reorganization") of Hamilton Lane Advisors, L.L.C. ("HLA") in connection with the Issuer's initial public offering (the "IPO"), the reporting person exchanged membership interests of HLA owned prior to the IPO for Class A Common Stock of the Issuer.

F2: Purchase of shares in Issuer's directed share program in connection with its initial public offering.

F3: Represents the number of shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's 2017 Equity Incentive Plan. The award was issued in substitution for existing awards of restricted interests in HLA that were issued annually in the years prior to the IPO, and the new award vests according to the same vesting schedule as the replaced awards: in four equal annual installments each March. Accordingly, one tranche will vest in 2017, one in 2018, one in 2019 and one in 2020.

F4: These options were granted under the Issuer's 2017 Equity Incentive Plan in substitution for outstanding options to purchase non-voting interests of HLA that were issued in 2007, prior to the IPO. The options being replaced were fully vested, and so the substitute award is fully vested.